HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer

Detalles Bibliográficos
Autores principales: Nakamura, Yoshiaki, Sawada, Kentaro, Fujii, Satoshi, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615873/
https://www.ncbi.nlm.nih.gov/pubmed/31354963
http://dx.doi.org/10.1136/esmoopen-2019-000530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615873/
https://www.ncbi.nlm.nih.gov/pubmed/31354963
http://dx.doi.org/10.1136/esmoopen-2019-000530

Ejemplares similares